Month: May 2023

Company updates stockholders on second quarter financial results; factory activities in Mishawaka, Indiana, and Tunica, Mississippi; Bollinger Motors Commercial Vehicles 4-6; Mullen Commercial Vehicles Class 1 and 3; and Mullen FIVE EV Crossover Program BREA, Calif., May 15, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces a financial update for its fiscal second quarter for the three and six months ended March 31, 2023. Financial Results Cash used in operating activities was $67.6 million, and cash flows used in investing activities was $97.4 million (primarily ELMS asset purchase for $93 million), offset by cash inflows from financing activities of $167.4 million for the six months ended March 31, 2023....

THORNTON, Colo., May 15, 2023 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (NASDAQ: ASTI) (“ASTI” or the “Company”), the leading U.S. innovator in the design and manufacture of featherweight, flexible thin-film photovoltaic (PV) solutions, announced today its results for the three months ended March 31, 2023. “During the quarter, we took decisive actions to reposition the Company as a leader in thin-film solar and made important progress towards commercializing our technology,” said Paul Warley, CEO of Ascent Solar Technologies. “We are excited about the recent acquisition of Flisom AG’s Swiss manufacturing assets, which tripled our production capacity and allow us to fulfill existing customer contracts in the luxury goods and building-integrated PV markets. “As evidence of our ongoing transformation, in just the last six...

GEORGE TOWN, Cayman Islands, May 15, 2023 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, reported results for the first quarter ended March 31, 2023. All comparisons are to the same prior year period unless otherwise noted. The company will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). First Quarter 2023 Financial HighlightsTotal revenue increased 68% to $32.9 million. Retail revenue increased 23% to $7.8 million. Bulk revenue increased 22% to $9.0 million. Services revenue increased 168% to $12.7 million. Manufacturing revenue increased to $3.4 million.  Net income from continuing operations attributable to company stockholders was $4.1 million...

Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights:Announced groundbreaking partnership with Cancer Research Horizons to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform....

NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in health and wellness solutions for people on the go, today reported results for the first quarter ended March 31, 2023. Business Highlights:Reflecting management’s commitment to better serve clients, optimize efficiencies, and deliver long-term growth:First quarter 2023 revenue at the Company’s XpresSpa business increased over 70% versus the 2022 first quarter. Demonstrating the effect of the Company’s cost-savings initiatives and deliver a leaner, more profitable XpresSpa business, first quarter 2023 general and administrative expenses decreased 12.7% sequentially and decreased 40.2% from the 2022 first quarter. The Company has integrated innovative health and wellness technologies, including fully autonomous HydroMassage...

SINGAPORE, May 16, 2023 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for the cryptocurrency mining community, today announced its unaudited financial results for the first quarter ended March 31, 2023. Linghui Kong, Chief Executive Officer of Bitdeer, commented, “We continued to deliver robust performance and maintained a sufficient cash flow during the first quarter, despite macroeconomic and crypto-market headwinds. While we recorded a net loss of $9.5 million, our non-IFRS adjusted profit was $2.8 million and non-IFRS adjusted EBITDA was $18.5 million. At the operational level, we proactively optimized our cost base by locking up a competitive price for 150MW electricity capacity in our Rockdale mining datacenter effectively until the end of 2023....

WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the first quarter ended March 31, 2023 and provided key business updates. “We are excited with the progress made during the first quarter, particularly related to the strengthening of our balance sheet by securing additional capital and moving forward with our plans to begin our SEISMiC extension study to advance istaroxime in cardiogenic shock,” said Craig Fraser, President and Chief Executive Officer of Windtree. “In addition, we are realizing the financial benefits of the portfolio prioritization undertaken in 2022, which along with other cost-cutting measures, resulted...

Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date Received U.S. Food and Drug Administration (FDA) clearance to begin a single ascending dose (SAD) clinical trial for ZKN-013 for the potential treatment of recessive Dystrophic Epidermolysis Bullosa (RDEB) with nonsense mutations WATERTOWN, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2023 and provided a business update. “We are approaching a significant milestone for Eloxx, with topline data, including kidney biopsy...